Meeting
2018 Gastrointestinal Cancers Symposium
A dose-escalation study of docetaxel, oxaliplatin and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer.
Authors
Yasushi Sato
Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
Yasushi Sato , Tamotsu Sagawa , Yasuo Takahashi , Hiroyuki Ohnuma , Kyoko Hamaguchi , Masahiro Hirakawa , Koshi Fujikawa , Koichi Okamoto , Hiroshi Miyamoto , Naoki Muguruma , Tetsuji Takayama
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
000015849
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 174)
DOI
10.1200/JCO.2018.36.4_suppl.174
Abstract #
174
Poster Bd #
L12
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Survival benefit of conversion therapy after intensive chemotherapy for unresectable metastatic gastric cancer: A propensity score-matched analysis.
First Author: Hiroyuki Ohnuma
First Author: Sebasti´n Mondaca
Poster
2015 Gastrointestinal Cancers Symposium
First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5- fluorouracil (DCF) plus panitumumab (P) in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction (GEJ): A phase II multicenter trial.
First Author: Gianluca Tomasello
Poster
2015 Gastrointestinal Cancers Symposium
Comparison of efficacy and tolerance of first-line palliative chemotherapy EOX and mDCF regimens in patients with locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma without overexpression of HER2 receptors.
First Author: Sebastian Ochenduszko